Table 6 β-Catenin membranous and nuclear expression in 187 non-lobular invasive breast carcinomas (17C2 clone)

From: β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

Parameter	N	Membranous negative	Membranous reduced	Membranous positive	P-value	Nuclear negative	Nuclear positive	P-value
Size—TNM	187				0.314			0.954
T1		10	7	83		93	7
T2		10	12	54		70	6
T3		2	1	8		10	1
Grade	184				0.353			0.291
1		1	2	19		22	0
2		3	4	39		43	3
3		18	13	85		105	11
Type	187				0.473			0.082
IDC		17	17	127		149	12
Mixed		3	3	12		18	0
Other		2	0	6		6	2
LVI	186				0.191			0.363
Negative		10	7	39		50	6
Positive		12	13	105		122	8
LN mets	182				0.450			0.007
Negative		10	8	47		55	10
Positive		12	11	94		113	4
ER	187				0.001			<0.001
Negative		11	3	22		26	10
Positive		11	17	123		147	4
PR	187				0.001			<0.001
Negative		13	4	33		40	10
Positive		9	16	112		133	4
HER2	187				0.461			0.132
Negative		19	15	124		144	14
Positive		3	5	21		29	0
HER2 CISH	177				0.182			0.227
Not amp		19	14	116		136	13
Amp		3	6	19		28	0
EGFR	187				0.269			0.040
Negative		18	17	133		158	10
Positive		4	3	12		15	4
CK14	186				0.028			<0.001
Negative		17	17	135		161	8
Positive		5	3	9		11	6
CK5/6	180				0.379			0.002
Negative		16	17	126		151	8
Positive		4	3	14		15	6
CK17	185				0.015			0.089
Negative		16	15	130		151	10
Positive		6	5	13		20	4
Basal CKs	186				0.037			0.002
Negative		15	15	126		149	7
Positive		7	5	18		23	7
Basal CKs or EGFR	186				0.007			<0.001
Negative		13	15	124		147	5
Positive		9	5	20		25	9
P53	173				0.004			0.059
Negative		9	12	101		116	6
Positive		13	6	32		44	7
MIB-1	172				0.026			0.014
<10%		2	9	56		63	4
10–30%		12	8	58		74	4
>30%		7	2	18		21	6
Molecular subtype^a	183				<0.001			<0.001
Basal		9	3	14		18	8
HER2		3	6	21		30	0
Luminal		8	11	108		123	4
Triple-negative	183				<0.001			<0.001
No		11	18	128		152	5
Yes		11	2	13		17	9
E-cadherin	167				0.004			0.269
Negative		9	4	15		24	4
Reduced		2	2	9		12	1
Normal		9	12	105		119	7
TOP2A	164				0.490			0.146
Low		7	7	60		71	3
High		13	11	66		80	10
TOP2A CISH	176				0.091			0.611
Not amp		19	15	126		147	13
Amp		3	4	9		16	0
Cyclin D1	174				0.002			0.021
Low		8	2	9		15	4
Intermediate		3	3	29		31	4
High		11	14	95		115	5
CCND1 CISH	187				0.181			1.000
Not amp		20	15	129		151	13
Amp		2	5	16		22	1
MYC CISH	157				0.860			0.108
Not amp		17	15	109		132	9
Amp		2	1	13		13	3
Caveolin 1	187				0.002			<0.001
Negative		15	19	134		161	7
Positive		7	1	11		12	7
Caveolin 2	165				0.238			0.001
Negative		18	17	118		145	8
Positive		3	0	9		7	5
Nestin	142				0.001			0.005
Negative		10	14	100		118	6
Positive		7	1	10		13	5
FOXA1	145				<0.001			0.003
Negative		12	4	22		30	8
Positive		6	10	91		103	4
Bcl2	143				0.003			0.292
Negative		12	6	35		48	5
Positive		4	9	77		86	4

amp: amplified; CISH: chromogenic in situ hybridization; ER: oestrogen receptor; IDC: invasive ductal carcinoma; LN mets: lymph node metastasis; LVI: lympho-vascular invasion; PR: progesterone receptor.
^aMolecular subtypes as defined by Nielsen immunohistochemical surrogate panel.³⁴
Significant P-values are shown in bold.

Back to article page

Table 6 β-Catenin membranous and nuclear expression in 187 non-lobular invasive breast carcinomas (17C2 clone)

Search

Quick links